Sunovion wins FDA approval for new Parkinson's drug
Photo | Grant Welker
Sunovion's Marlborough headquarters
Marlborough pharmaceutical firm Sunovion said Thursday it has received federal approval for the first drug for Parkinson's disease which dissolves under the tongue.
The sublingual drug, called KYNMOBI, is used to treat what's known as OFF episodes for Parkinson's patients, when they experience symptoms like tremor or difficulty walking.
Sunovion, which got U.S. Food and Drug Administration approval, said the regulatory sign-off will give Parkinson's patients a new way of administering a drug to treat episodes. The drug is a film dissolving under the tongue, allowing patients to treat episodes as they occur.
More than 17,000 Massachusetts residents have Parkinson's, according to Sunovion, and nearly 1 million nationwide, according to the Parkinson's Foundation. Within four to six years of a Parkinson's diagnosis, 40% to 60% of patients experience OFF episodes, Sunovion said.
In trials, Sunovion said it found those treated with KYNMOBI experienced significant improvements in motor symptoms within 30 minutes.
WBJ Web Partners
Most Recent
Most Recent
0 Comments